Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUNRISE secukinumab trial in moderate to severe hidradenitis suppurativa
NL-OMON52934Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Dec 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of secukinumab in hidradenitis suppurativa (HS) (3 arms), sponsored by Novartis. Primary endpoint: Achievement of HiSCR at Week 16. Started Dec 2019; status: active, not recruiting.
02
Drugs
secukinumab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NL-OMON52934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52934.